Immunogenicity and Safety of the M72/AS01E Candidate Vaccine Against Tuberculosis: A Meta-Analysis

Immunogenicity and Safety of the M72/AS01E Candidate Vaccine Against Tuberculosis: A Meta-Analysis

Background: Currently, there is no tuberculosis (TB) vaccine recommended for use in latent TB infections and healthy adults. M72/AS01E is a new peptide vaccine currently under development, which may improve protection against TB disease. This vaccine has been investigated in several phase I/II clini...

Full description

Bibliographic Details
Main Authors: Zhenhua Ji, Miaomiao Jian, Taigui Chen, Lisha Luo, Lianbao Li, Xiting Dai, Ruolan Bai, Zhe Ding, Yunfeng Bi, Shiyuan Wen, Guozhong Zhou, Manzama-Esso Abi, Aihua Liu, Fukai Bao
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Immunology
Subjects:
vaccine
tuberculosis
M72/AS01E
immunogenicity
safety
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02089/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.02089/full

Similar Items